These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145 [TBL] [Abstract][Full Text] [Related]
24. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a). Franke V; Berger DMS; Klop WMC; van der Hiel B; van de Wiel BA; Ter Meulen S; Wouters MWJM; van Houdt WJ; van Akkooi ACJ Int J Cancer; 2019 Aug; 145(4):974-978. PubMed ID: 30694555 [TBL] [Abstract][Full Text] [Related]
25. Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience. Carr MJ; Sun J; DePalo D; Rothermel LD; Song Y; Straker RJ; Baecher K; Louie RJ; Stahlie EHA; Wright GP; Naqvi SMH; Kim Y; Sarnaik AA; Karakousis GC; Lowe MC; Delman KA; van Akkooi ACJ; Ollila DW; Collichio F; Zager JS Ann Surg Oncol; 2022 Feb; 29(2):791-801. PubMed ID: 34648098 [TBL] [Abstract][Full Text] [Related]
26. Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer. Sheth RA; Murthy R; Hong DS; Patel S; Overman MJ; Diab A; Hwu P; Tam A JAMA Netw Open; 2020 Jul; 3(7):e207911. PubMed ID: 32725245 [TBL] [Abstract][Full Text] [Related]
27. Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. Sun L; Funchain P; Song JM; Rayman P; Tannenbaum C; Ko J; Mcnamara M; Marcela Diaz-Montero C; Gastman B J Immunother Cancer; 2018 May; 6(1):36. PubMed ID: 29764498 [TBL] [Abstract][Full Text] [Related]
29. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. Andtbacka RH; Ross M; Puzanov I; Milhem M; Collichio F; Delman KA; Amatruda T; Zager JS; Cranmer L; Hsueh E; Chen L; Shilkrut M; Kaufman HL Ann Surg Oncol; 2016 Dec; 23(13):4169-4177. PubMed ID: 27342831 [TBL] [Abstract][Full Text] [Related]
30. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma. Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610 [TBL] [Abstract][Full Text] [Related]
31. A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries. van Akkooi ACJ; Haferkamp S; Papa S; Franke V; Pinter A; Weishaupt C; Huber MA; Loquai C; Richtig E; Gokani P; Öhrling K; Louie KS; Mohr P Adv Ther; 2021 Feb; 38(2):1245-1262. PubMed ID: 33368016 [TBL] [Abstract][Full Text] [Related]
32. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma. Chesney J; Awasthi S; Curti B; Hutchins L; Linette G; Triozzi P; Tan MCB; Brown RE; Nemunaitis J; Whitman E; Windham C; Lutzky J; Downey GF; Batty N; Amatruda T Melanoma Res; 2018 Feb; 28(1):44-51. PubMed ID: 29176501 [TBL] [Abstract][Full Text] [Related]
33. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience. Perez MC; Miura JT; Naqvi SMH; Kim Y; Holstein A; Lee D; Sarnaik AA; Zager JS Ann Surg Oncol; 2018 Dec; 25(13):3960-3965. PubMed ID: 30298318 [TBL] [Abstract][Full Text] [Related]
34. False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC). Mulder EEAP; Stahlie EHA; Verver D; Lemstra C; Been LB; Mooyaart AL; Brabander T; Vegt E; Verburg FA; van der Veldt AAM; Verhoef C; van Akkooi ACJ; Grünhagen DJ J Surg Oncol; 2021 Dec; 124(7):1161-1165. PubMed ID: 34235758 [TBL] [Abstract][Full Text] [Related]
35. A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma. Yamazaki N; Isei T; Kiyohara Y; Koga H; Kojima T; Takenouchi T; Yokota K; Namikawa K; Yi M; Keegan A; Fukushima S Cancer Sci; 2022 Aug; 113(8):2798-2806. PubMed ID: 35656636 [TBL] [Abstract][Full Text] [Related]
37. Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report. Hsu AC; Kokot NC; Eisenberg BL; Thomas JS Oral Oncol; 2020 Dec; 111():104899. PubMed ID: 32665184 [TBL] [Abstract][Full Text] [Related]
38. Panniculitis in a patient with pathologic complete response to talimogene laherparepvec treatment for recurrent, in-transit melanoma. Long TH; Shinohara MM; Argenyi ZB; Thompson JA; Gardner JM J Cutan Pathol; 2018 Nov; 45(11):864-868. PubMed ID: 30054925 [TBL] [Abstract][Full Text] [Related]
39. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. Chesney J; Puzanov I; Collichio F; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan TF; Hauschild A; Lebbé C; Chen L; Kim JJ; Gansert J; Andtbacka RHI; Kaufman HL J Clin Oncol; 2018 Jun; 36(17):1658-1667. PubMed ID: 28981385 [TBL] [Abstract][Full Text] [Related]
40. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]